E
AZN icon

Ergoteles’s AstraZeneca AZN Stock Holding History

Ergoteles’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,348
Closed -$765K – 108
2023
Q2 		$765K Sell
5,348
-14,612
-73% -$2.15M 0.04% 532
2023
Q1 		$2.77M Buy
19,960
+4,661
+30% +$627K 0.11% 186
2022
Q4 		$2.07M Buy
15,299
+4,117
+37% +$516K 0.08% 269
2022
Q3 		$1.23M Sell
11,182
-2,219
-17% -$282K 0.04% 411
2022
Q2 		$1.77M Buy
13,401
+3,110
+30% +$408K 0.05% 349
2022
Q1 		$1.36M Buy
+10,291
New +$1.23M 0.05% 348
2021
Q4 		– Sell
-1,997
Closed -$240K – 1236
2021
Q3 		$240K Buy
+1,997
New +$232K 0.01% 899

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ergoteles's AZN Position: Q3 2023 in Review

Ergoteles sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 5,348 shares — an estimated $765K sold.

Ergoteles first reported a position in AZN in Q3 2021 and held it in 7 quarters. The position peaked at $2.77M in Q1 2023. 1,074 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

  • Ergoteles reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 5,348 AstraZeneca shares in Q3 2023, an estimated $765K.
  • Ergoteles first reported a position in AstraZeneca in Q3 2021 and held it in 7 quarters.
  • Ergoteles's AstraZeneca position peaked at $2.77M in Q1 2023.
  • 1,074 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.